Sarepta licenses Summit’s DMD drugs | Chemical & Engineering News
Volume 94 Issue 40 | p. 15 | Concentrates
Issue Date: October 10, 2016

Sarepta licenses Summit’s DMD drugs

Department: Business
Keywords: rare disease, biotech, Duchenne, DMD

In its second partnership since FDA approval last month of eteplirsen, its exon-skipping Duchenne muscular dystrophy treatment, Sarepta Therapeutics has licensed the European rights to Summit Therapeutics’ utrophin modulator pipeline. The deal includes ezutromid, which is in a Phase II study for treating DMD. Summit will get $40 million up front and could reap another $522 million in milestone payments. Late last month, Sarepta teamed with Catabasis to study combining its exon-skipping drugs with Catabasis’s NF-κB inhibitors.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment